Pfizer Inc. looked to secure its future in the anaplastic lymphoma kinase (ALK)-positive metastatic non-small-cell lung cancer (NSCLC) market with FDA approval of Lorbrena (lorlatinib), a third-generation ALK tyrosine kinase inhibitor (TKI), to treat individuals whose disease progressed on its first-line treatment, Xalkori (crizotinib), and at least one other ALK inhibitor for metastatic disease or on Alecensa (alectinib, Genentech/Roche Holding AG) or Zykadia (ceritinib, Novartis AG) as first-line ALK inhibitor therapy for metastatic disease.